What Are the Side Effects of BCG Treatment for Bladder Cancer?

BCG (Bacillus Calmette-Guérin) treatment for bladder cancer causes side effects in the vast majority of patients, with bladder irritation being by far the most common. Roughly nine out of ten people experience some degree of cystitis, and symptoms like urinary urgency, burning, and frequent trips to the bathroom typically appear within hours of each instillation. These effects are usually self-limiting, resolving within a couple of days, but they can be intense enough to make some patients consider stopping treatment altogether. Serious systemic complications are genuinely rare, though they demand quick recognition when they do occur.

Why BCG Triggers Side Effects in the First Place

BCG is a live, weakened strain of Mycobacterium bovis, a bacterium related to the one that causes tuberculosis. When it is instilled directly into the bladder through a catheter, it attaches to the bladder lining and gets internalized by both normal urothelial cells and cancer cells. This sets off a powerful immune cascade: the bladder’s own cells begin acting as presenters of BCG and tumor antigens, recruiting waves of immune cells including T-cells, natural killer cells, macrophages, and granulocytes to the area. Those immune cells then attack the cancer through direct cytotoxicity and by releasing cell-killing factors like TRAIL (a protein that triggers cancer cell death).¹ The catch is that this aggressive local immune response doesn’t distinguish cleanly between “productive anti-tumor inflammation” and “inflammation you feel as painful side effects.” The bladder irritation, swelling, and discomfort are essentially collateral damage from the same immune activation that makes BCG effective against cancer.

BCG also has a direct cytotoxic effect on cancer cells, triggering programmed cell death through several pathways, including generating reactive oxygen species that injure tumor cells. At the same time, the strong shift toward an inflammatory immune response (dominated by Th1-type immunity) means the balancing, tissue-repair arm of the immune system (Th2-type) gets suppressed. That imbalance is part of why the bladder wall can become so irritated during treatment.²

Local Bladder Symptoms

Cystitis is the hallmark side effect of BCG therapy. In one large series of over 1,200 patients, cystitis occurred in 91% of those treated.³ The symptoms are what you would expect from severe bladder inflammation: urinary urgency (the sudden, hard-to-ignore need to urinate), increased frequency, burning or pain during urination (dysuria), and pelvic discomfort.⁴ Some patients also notice blood in the urine (hematuria), and temporary incontinence is not unusual during flare-ups.

These symptoms typically start a few hours after instillation and peak within the first day or two. For most people they settle down within 48 to 72 hours, though some have symptoms that linger longer. The severity tends to vary from cycle to cycle and from patient to patient. For some, it feels like a bad urinary tract infection; for others, it can be debilitating enough that they struggle to leave the house for a day or two after each treatment. Importantly, these local effects are not a sign that something has gone wrong. They are expected consequences of the immune response that BCG is designed to provoke.

Fever, Fatigue, and General Malaise

Beyond the bladder itself, many patients develop what doctors call “flu-like” systemic symptoms. Low-grade fever (under 38.5°C or about 101°F), chills, body aches, and a general feeling of being unwell are common after instillations. The incidence of general malaise and fever is high enough to be considered a routine part of the treatment experience rather than an alarm signal.⁵ These symptoms usually resolve within 24 to 48 hours and can often be managed with over-the-counter antipyretics like acetaminophen or ibuprofen.

A low-grade fever that clears up on its own is not a reason to stop treatment. However, a fever above 39.5°C (about 103°F) that persists beyond 48 hours, or a fever accompanied by worsening constitutional symptoms like drenching sweats and rigors, is a different story. Persistent high fever can be an early sign of systemic BCG infection, which requires prompt medical attention.

Rare but Serious Systemic Complications

The most feared complication of intravesical BCG is systemic BCG-osis, a condition in which the live BCG organisms spread beyond the bladder into the bloodstream and other organs. In one single-institution series, about 4% of patients developed systemic BCG infection, with miliary tuberculosis (tiny granulomas scattered through the lungs and other organs) being the most common form.⁶ A pooled analysis from the same study found that among patients who did develop systemic BCG infection, disseminated disease was the most common presentation (about a third of cases), followed by genitourinary infections and bone and joint infections.

When BCG reaches the lungs, it can cause BCG pneumonitis, which may show up on imaging as bilateral miliary nodules scattered across both lungs. In one case report, a patient developed lung micronodularity after BCG treatment, and a liver biopsy confirmed granulomatous inflammation even though cultures from blood, urine, sputum, and bronchial wash all came back negative.⁷ That negative-culture pattern is actually typical: BCG-related organ inflammation is often driven by the immune reaction to the organisms rather than by overwhelming bacterial infection, making it hard to confirm on standard cultures.

Other organs that can be affected include the liver (granulomatous hepatitis), kidneys, prostate, and, less commonly, bone. Granulomatous prostatitis has been observed in a substantial fraction of men after BCG therapy. The key point about all of these organ-specific complications is that they are individually uncommon but collectively represent a real, if small, risk profile that patients and their doctors need to watch for.

Joint Problems and Reactive Arthritis

BCG instillation can trigger reactive arthritis, a type of joint inflammation that is not caused by direct bacterial infection of the joint but instead by the immune system’s response to BCG. The incidence in Western countries ranges from roughly 0.5% to about 6% of treated patients.⁸ Symptoms tend to appear a few weeks after an instillation and can involve one or several joints, sometimes accompanied by eye inflammation (conjunctivitis or uveitis).

Distinguishing reactive arthritis from true septic (infected) arthritis matters because the treatments are very different. Clues pointing toward reactive arthritis include involvement of multiple joints and an onset a few weeks after BCG, whereas septic arthritis from BCG organisms typically shows up months later and tends to affect a single joint.⁹ Joint fluid examination is usually recommended to rule out infection. When reactive arthritis is confirmed, treatment starts with anti-inflammatory drugs like NSAIDs. More stubborn cases may need corticosteroids, either as eye drops for ocular involvement, injected directly into a swollen joint, or taken orally.⁸ If, however, the joint is actually infected with BCG organisms, antitubercular antibiotics are required for months.

What Raises Your Risk of Worse Side Effects

Not everyone faces the same odds of severe complications. The single most important risk factor is a traumatic catheterization, meaning one that causes bleeding or abrasion to the bladder lining. When the protective mucosal barrier is disrupted, BCG organisms can access the bloodstream far more easily than they would through an intact bladder wall.¹⁰ This is why the prescribing label for TICE BCG (one of the commonly used formulations) explicitly states that treatment should be postponed for at least one week after transurethral resection, biopsy, traumatic catheterization, or any episode of visible blood in the urine.¹¹

Other factors that increase the risk of systemic side effects include active cystitis at the time of instillation, immunosuppression, and diabetes.¹⁰ Recognizing these risk factors and timing instillations carefully around them is one of the most effective ways to keep severe toxicity rates low.¹²

How Side Effects Differ Between Induction and Maintenance

BCG therapy is typically delivered in two phases. The induction phase involves a weekly instillation for six weeks. If the tumor responds, patients move into a maintenance phase with periodic instillations over one to three years. A systematic review of patient-reported symptoms found something that might seem counterintuitive: the induction phase tends to produce more intense side effects on a per-instillation basis than maintenance does. However, severe side effects that lead to stopping treatment altogether occurred almost twice as often in patients on maintenance schedules, simply because those patients are exposed to BCG over a much longer period.¹³

This has practical implications. If you are going through induction and finding the side effects rough, it is worth knowing that individual sessions during maintenance tend to be somewhat easier to tolerate. On the other hand, the cumulative toll of repeated treatments over months or years means that the overall chance of eventually hitting a side effect severe enough to end your treatment is higher with longer courses.

How Severe Side Effects Are Treated

For persistent cystitis that lasts more than two days or does not respond to basic symptom relief, the standard first step is isoniazid (an antitubercular drug) at 300 mg daily. Isoniazid helps control symptoms and prevents progressive BCG infection. If that is not enough after one to two weeks, a second drug, rifampicin, is added. For more serious organ involvement like pneumonitis, hepatitis, or kidney inflammation, rifampicin is started immediately alongside isoniazid rather than waiting to see if isoniazid alone works.¹⁴

One important detail: prophylactic isoniazid (given routinely to prevent side effects before they happen) is not recommended. Animal studies have shown that isoniazid given before BCG can blunt the immune stimulation that makes the treatment work against cancer. So antitubercular drugs are reserved for treating complications, not preventing them.

In cases of full-blown systemic BCG-osis, which can be life-threatening, the treatment typically involves a triple-drug antitubercular regimen (often ethambutol, isoniazid, and rifampicin) along with corticosteroids to control the runaway immune response. This combination has been reported to stabilize critically ill patients, though recovery may require a prolonged hospital stay and months of ongoing therapy.¹⁵

Can a Lower Dose Reduce Side Effects Without Losing Effectiveness?

Given how common and disruptive side effects are, researchers have studied whether using a reduced dose of BCG (typically one-third of the standard dose) could preserve anti-cancer efficacy while lowering toxicity. A meta-analysis looking at this question found that reduced doses did cut both systemic and local side effects. Systemic side effects were roughly halved, and local side effects also dropped meaningfully compared to full-dose treatment.¹⁶

The tradeoff, however, is not entirely clean. That same analysis found a trend toward higher recurrence rates in the reduced-dose groups, though the difference did not reach clear statistical significance, and progression rates were similar between the two doses. A large randomized European trial comparing one-third dose to full dose found no significant difference in side effects between the groups, complicating the picture further.¹⁷ The evidence is mixed enough that dose reduction remains a reasonable option in certain situations, particularly for patients struggling with tolerability, but it is not a universally adopted standard.

The Role of Prophylactic Antibiotics

Another strategy for managing BCG side effects involves giving a short course of fluoroquinolone antibiotics (like ofloxacin) after each instillation. Some evidence suggests that prophylactic quinolone use reduces the incidence of adverse events and helps patients complete their scheduled instillations on time.¹⁸ Guidelines have noted that giving ofloxacin 200 mg twice after each BCG session appears to improve tolerability without undermining effectiveness.¹⁹

One concern with using antibiotics alongside a live bacterial treatment is whether they might reduce the anti-cancer effect of BCG by killing the organisms before they can do their job. Research looking at recurrence-free survival in patients who received antibiotics alongside BCG found no significant difference compared to those who did not receive antibiotics, suggesting the anti-cancer efficacy is maintained.²⁰ This is still an evolving area, and practices vary across institutions.

When People Stop Treatment Early

Side effects are not just an inconvenience; they are a leading reason patients abandon a treatment that has a strong track record against their cancer. Overall, about 7% of BCG-treated patients discontinue specifically because of adverse events.²¹ But that number can climb dramatically with intensive or prolonged maintenance schedules. One study reported withdrawal rates as high as 90% during the first year of an intensive BCG schedule, with urinary frequency, pain, and cystitis being the most common reasons cited.²²

Age plays a significant role. Patients 70 and older are considerably more likely to stop BCG early, with nearly half withdrawing within the first year in one analysis.²² This matters because incomplete BCG treatment leaves patients with reduced protection against cancer recurrence and progression. The challenge for clinicians is finding the balance between pushing through tolerable side effects (which are a sign the treatment is working as intended) and recognizing when the treatment burden has crossed the line into diminishing returns for an individual patient. Practical measures like timing instillations around daily commitments, using prophylactic ofloxacin, adjusting the dose when appropriate, and making sure patients know ahead of time what to expect can all help more people get through the full course.

Granulomatous Prostatitis in Men

One side effect worth highlighting separately, because it can cause confusion on imaging and biopsy, is granulomatous prostatitis. BCG organisms instilled in the bladder can travel into the prostate through the prostatic ducts, triggering granuloma formation in the prostate tissue. This has been observed in a large fraction of men after BCG therapy, with estimates suggesting it occurs in roughly four out of ten male patients.²³ In most cases it does not cause overt symptoms, but it can produce elevated PSA levels and prostate nodules that mimic prostate cancer on a physical exam or imaging. Urologists familiar with a patient’s BCG history will factor this in before ordering a prostate biopsy, but the potential for a diagnostic false alarm is real if the treatment history is not communicated clearly between providers.